Report
BioNTech SE : Less demand for coronavirus booster shots expected
>What to assume for Comirnaty going forward? - If the European Commission now also approves the company’s bivalent vaccine booster against the wild-type strain and the BA.4/BA.5 subvariants of Omicron in individuals at least 12 years of age after the CHMP gave a positive recommendation on 12 September, the newly available booster vaccines would be bivalent vaccines shots against the wild-type strain of SARS-CoV-2 and the BA.4 and BA.5 subvariants of the Omicron varian...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Oliver Metzger
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.